Compare CBAT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBAT | PLRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9M | 65.6M |
| IPO Year | 2006 | 2020 |
| Metric | CBAT | PLRX |
|---|---|---|
| Price | $0.82 | $1.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 263.8K | ★ 360.3K |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $195,189,306.00 | N/A |
| Revenue This Year | $66.88 | N/A |
| Revenue Next Year | $41.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $0.46 | $1.02 |
| 52 Week High | $1.24 | $1.95 |
| Indicator | CBAT | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.23 | 60.08 |
| Support Level | $0.77 | $1.12 |
| Resistance Level | $0.89 | $1.37 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 75.46 | 64.29 |
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments; CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe, India, Africa, and other regions.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.